Results 191 to 200 of about 23,252 (297)

Spondyloarthritis Associated With Collagenous Colitis—Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Collagenous colitis (CC) is a subtype of microscopic colitis characterized by chronic watery diarrhea with normal endoscopic findings. Although often linked to autoimmune diseases, its association with spondyloarthropathy (SpA) is rare and poorly documented.
Charlotte Bouvy   +4 more
wiley   +1 more source

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis [PDF]

open access: yes, 2015
Anne Bertrand   +4 more
core   +1 more source

B‐Lymphoblastic Leukemia With Isolated Central Nervous System Relapse Mimicking a Vestibular Schwannoma

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT The central nervous system (CNS) is the most common site of extramedullary relapse in acute lymphoblastic leukemia (ALL). However, the diagnosis may be challenging due to its protean manifestations. A 64‐year‐old male reported right‐sided hearing loss with intermittent bilateral occipitotemporal headaches during a clinic follow‐up for Ph + B ...
Jun Yen Ng   +3 more
wiley   +1 more source

[Valproic Acid-Induced Lymphocytic Colitis in a Pediatric Patient: A Case report]. [PDF]

open access: yesActa Gastroenterol Latinoam
Tagliaferro GJ   +3 more
europepmc   +1 more source

Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies

open access: yesCancer, Volume 132, Issue 9, 1 May 2026.
Abstract Background The dose escalation phase of a first‐in‐human (FIH) study demonstrated acceptable safety and preliminary antitumor activity of fianlimab (anti‐lymphocyte activation gene‐3 [LAG‐3]) as monotherapy and in combination with cemiplimab (anti‐programmed cell death‐1 [PD‐1]). Here, the authors present safety and clinical activity data from
Tae Min Kim   +25 more
wiley   +1 more source

Fungal Polysaccharides as Next‐Generation Bioactive: Advances in Structure–Activity Mapping, Mode of Action, and Biotechnological Horizons

open access: yesFood Frontiers, Volume 7, Issue 3, May 2026.
ABSTRACT Fungal polysaccharides (FPs) represent a diverse class of bioactive macromolecules widely studied for their nutritional, therapeutic, and biotechnological value. This review synthesizes recent advances (2020–2025) in the structural characterization, biological functions, and translational potential of FPs.
Muhammad Aaqil   +6 more
wiley   +1 more source

Natural Products as the Modulators of Gut Microbiota: A Pool for the Development of New Treatment Against Obesity?

open access: yesFood Frontiers, Volume 7, Issue 3, May 2026.
Natural compounds regulate gut microbiota by improving microbial balance and increasing probiotics, which boost short‐chain fatty acid production to alleviate insulin resistance and inflammation. Additionally, they stimulate appetite‐suppressing hormones through bile acid signaling, while inhibiting pathogenic bacteria to repair intestinal barrier ...
Hongchao Yuan   +7 more
wiley   +1 more source

Corrigendum: Biomarkers and Microscopic Colitis: An Unmet Need in Clinical Practice

open access: yesFrontiers in Medicine, 2020
Laura Francesca Pisani   +8 more
doaj   +1 more source

Rosa roxburghii‐Derived Exosome‐Like Nanovesicles Alleviate Ulcerative Colitis Based on Th17/Treg Immune Balance and Gut Microbiota Modulation

open access: yesFood Frontiers, Volume 7, Issue 3, May 2026.
Rosa roxburghii‐derived exosome‐like nanovesicles target the intestine, repairing barriers, regulating gut microbiota, balancing Th17/Treg, and combating oxidative stress/inflammation to alleviate colitis, a promising UC therapy. ABSTRACT Plant‐derived nanovesicles (PDVs), an innovative and bioactive form of natural products, are key mediators of ...
Yuanyuan Wang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy